Tirzepatide
The dual GIP/GLP-1 behind Zepbound® and Mounjaro® — compounded, at a lower cash price.
Tirzepatide activates two gut-hormone receptors — GIP and GLP-1 — for appetite reduction and metabolic effect. It’s the molecule behind Zepbound®/Mounjaro®, shown to deliver strong average weight loss; the compounded form offers it at a lower cash price for appropriate patients.
Prescription required. Final clinical decisions rest with the prescribing physician.
What is Tirzepatide?
Tirzepatide is a dual agonist — it activates both the GIP and GLP-1 receptors, which together reduce appetite and improve metabolic signaling. In trials, tirzepatide produced some of the largest average weight-loss results of any medication to date.
The compounded form is prepared by licensed compounding pharmacies and is not an FDA-approved finished product; availability can change with FDA guidance. The physician confirms candidacy and sets your titration.
Potential benefits
Dual GIP/GLP-1 action
Activates two receptors for appetite and metabolic effect.
Strong average results
Among the most effective weight-loss molecules in trials.
Once-weekly
A single weekly injection, titrated gradually.
Lower cash price
A more affordable option than brand for appropriate patients.
How it works
How it’s taken
A once-weekly subcutaneous injection, titrated up over several weeks. The physician sets your schedule.
Typical protocol
Gradual dose escalation to a maintenance dose, with progress and tolerability check-ins.
How ordering works
Complete the intake
Share your goals, health history, and current medications — about 5 minutes.
Physician evaluation
An independent, board-certified physician reviews your intake and, if appropriate, prescribes Tirzepatide with a dosing protocol.
Compounded & shipped
The prescription is filled by a licensed compounding pharmacy and shipped to your door with instructions.
What to know before Tirzepatide
Tirzepatide is a bioactive compound. The physician you’re connected with will review the relevant risks and contraindications for your situation before prescribing.
- •Common side effects are nausea and other GI effects, usually easing with titration.
- •Not for personal/family history of medullary thyroid carcinoma or MEN 2, or with certain GI conditions.
- •Disclose your full history and current medications; the physician confirms candidacy.
- •Compounded tirzepatide is not an FDA-approved finished product; availability can change with FDA guidance.
Tirzepatide FAQ
Is compounded tirzepatide the same as Zepbound/Mounjaro?
It’s the same active molecule (tirzepatide), prepared by a compounding pharmacy rather than the brand manufacturer — typically at a lower cash price.
How is tirzepatide different from semaglutide?
Tirzepatide activates two receptors (GIP + GLP-1) vs semaglutide’s one (GLP-1), and showed larger average weight loss in trials. The physician helps you choose.
How is it taken?
A once-weekly subcutaneous injection, titrated up gradually.
Is it FDA-approved?
Brand tirzepatide is FDA-approved; the compounded form is not a finished FDA-approved product and is prescribed under physician supervision. Availability can change with FDA guidance.
How much does it cost?
Compounded tirzepatide starts from $249/month. Final pricing is confirmed after your physician evaluation. The initial evaluation is free.
Ready to start Tirzepatide?
Complete a short medical intake — a supervising physician reviews it and, if appropriate, writes your prescription, and a licensed pharmacy ships to your door.
Pricing & regulatory note: The $249/mo price is an indicative starting point confirmed by the compounding pharmacy after physician evaluation. Tirzepatide is not an FDA-approved finished drug product; it is prepared by licensed compounding pharmacies and prescribed off-label. FDA guidance on peptide compounding continues to evolve and availability can change. A prescription is required.